Literature DB >> 33580056

Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine.

Ting Zhao1, Jing Li1, Yuting Fu1, Hui Ye1, Xiaochang Liu1, Guoliang Li1, Xiaolei Yang1, Jingsi Yang2.   

Abstract

The impact of intestinal microbiota on mucosal antibody response to the polio vaccine is poorly understood. We examined changes in vaccine-induced intestinal mucosal immunity to poliovirus by measuring the immunoglobulin A (IgA) antibody levels in stool samples collected from 107 infants in China, and the samples were collected 14 days after different sequential vaccinations combining inactivated polio vaccine (IPV) with oral poliovirus vaccine (OPV). Gut microbiota were identified using 16S ribosomal RNA sequencing 28 days before, 14 days before, and at the last dose of OPV. Vaccine-induced type 2-specific mucosal IgA showed a decrease after switching from trivalent to bivalent OPV (bOPV) (positive rate of polio type 2-specific mucosal IgA, 16.7%, 11.8%, and 45.9% for IPV + 2bOPV, 2IPV + bOPV, and 2IPV + trivalent OPV groups, respectively). The composition of the gut microbiome was significantly different, a higher abundance of Firmicutes and a lower abundance of Actinobacteria were observed in IgA-negative infant (n = 66) compared with IgA-positive infants (n = 39), and the gut microbiota were more diverse in IgA-negative infants on the day of OPV inoculation. The abundance of Clostridia was concomitant with a significantly lower conversion rate of mucosal IgA responses to the polio vaccine. The composition of the gut microbiome may affect the intestinal mucosal IgA response to the polio vaccine.

Year:  2020        PMID: 33580056     DOI: 10.1038/s41541-020-0194-5

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN: 2059-0105            Impact factor:   7.344


  51 in total

Review 1.  SeXX matters in immunity.

Authors:  J G Markle; E N Fish
Journal:  Trends Immunol       Date:  2013-11-13       Impact factor: 16.687

Review 2.  Polio endgame: the global introduction of inactivated polio vaccine.

Authors:  Manish Patel; Simona Zipursky; Walt Orenstein; Julie Garon; Michel Zaffran
Journal:  Expert Rev Vaccines       Date:  2015-01-19       Impact factor: 5.217

Review 3.  Performance of rotavirus vaccines in developed and developing countries.

Authors:  Victoria Jiang; Baoming Jiang; Jacqueline Tate; Umesh D Parashar; Manish M Patel
Journal:  Hum Vaccin       Date:  2010-07

Review 4.  A small jab - a big effect: nonspecific immunomodulation by vaccines.

Authors:  Christine S Benn; Mihai G Netea; Liisa K Selin; Peter Aaby
Journal:  Trends Immunol       Date:  2013-05-14       Impact factor: 16.687

5.  RotaTeq: Progress toward developing world access.

Authors:  Michelle G Goveia; Christopher B Nelson; Max Ciarlet
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

6.  Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion.

Authors:  S Valtanen; M Roivainen; L Piirainen; M Stenvik; T Hovi
Journal:  J Infect Dis       Date:  2000-06-27       Impact factor: 5.226

Review 7.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

8.  Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.

Authors:  H O Hallander; M Paniagua; F Espinoza; P Askelöf; E Corrales; M Ringman; J Storsaeter
Journal:  Vaccine       Date:  2002-11-22       Impact factor: 3.641

9.  Understanding reduced rotavirus vaccine efficacy in low socio-economic settings.

Authors:  Benjamin A Lopman; Virginia E Pitzer; Rajiv Sarkar; Beryl Gladstone; Manish Patel; John Glasser; Manoj Gambhir; Christina Atchison; Bryan T Grenfell; W John Edmunds; Gagandeep Kang; Umesh D Parashar
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

10.  Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.

Authors:  Peter F Wright; Ruth I Connor; Wendy F Wieland-Alter; Anne G Hoen; Austin W Boesch; Margaret E Ackerman; M Steven Oberste; Chris Gast; Elizabeth B Brickley; Edwin J Asturias; Ricardo Rüttimann; Ananda S Bandyopadhyay
Journal:  Lancet Infect Dis       Date:  2016-09-13       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.